BR0107921A - Cristalização seletiva de sódio de ácido 3-piridil-1-hidroxietilideno-1,1-bisfosfÈnico como o monohidrato ou hemipentahidrato - Google Patents

Cristalização seletiva de sódio de ácido 3-piridil-1-hidroxietilideno-1,1-bisfosfÈnico como o monohidrato ou hemipentahidrato

Info

Publication number
BR0107921A
BR0107921A BR0107921-2A BR0107921A BR0107921A BR 0107921 A BR0107921 A BR 0107921A BR 0107921 A BR0107921 A BR 0107921A BR 0107921 A BR0107921 A BR 0107921A
Authority
BR
Brazil
Prior art keywords
hemipentahydrate
pyridyl
monohydrate
hydroxyethylidene
bisphosphonic acid
Prior art date
Application number
BR0107921-2A
Other languages
English (en)
Other versions
BRPI0107921B1 (pt
BRPI0107921B8 (pt
Inventor
Fredrick Dana Cazer
Gregory Eugene Perry
Dennis Michael Billings
Nacy Lee Redman-Furey
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22656866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0107921(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR0107921A publication Critical patent/BR0107921A/pt
Publication of BRPI0107921B1 publication Critical patent/BRPI0107921B1/pt
Publication of BRPI0107921B8 publication Critical patent/BRPI0107921B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"CRISTALIZAçãO SELETIVA DE SóDIO DE áCIDO 3-PIRIDIL-1-HIDROXIETILIDENO-1,1-BISFOSFÈNICO COMO O MONOHIDRATO OU HEMIPENTAHIDRATO". A presente invenção refere-se ao monohidrato e hemipentahidrato de sódio de ácido de 3-piridil-1-hidroxietilideno-1,1-bisfosfónico, métodos de preparação do hemipentahidrato ou monohidrato através do controle da temperatura de nucleação e a taxa de cristalização e composições farmacêuticas contendo uma ou ambas das formas de hidratos.
BRPI0107921A 2000-02-01 2001-02-01 processo para produzir seletivamente monohidrato e hemipentahidrato de ácido 3-piridil-1-hidroxietilideno-1,1-bisfosfônico de sódio BRPI0107921B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17950500P 2000-02-01 2000-02-01
US60/179,505 2000-02-01
PCT/US2001/003336 WO2001056983A2 (en) 2000-02-01 2001-02-01 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate

Publications (3)

Publication Number Publication Date
BR0107921A true BR0107921A (pt) 2002-10-22
BRPI0107921B1 BRPI0107921B1 (pt) 2020-11-10
BRPI0107921B8 BRPI0107921B8 (pt) 2021-05-25

Family

ID=22656866

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0107921A BRPI0107921B8 (pt) 2000-02-01 2001-02-01 processo para produzir seletivamente monohidrato e hemipentahidrato de ácido 3-piridil-1-hidroxietilideno-1,1-bisfosfônico de sódio

Country Status (33)

Country Link
US (1) US6410520B2 (pt)
EP (1) EP1252170B2 (pt)
JP (5) JP2003521532A (pt)
KR (1) KR100549038B1 (pt)
CN (1) CN1183148C (pt)
AR (1) AR030187A1 (pt)
AT (1) ATE273984T1 (pt)
AU (1) AU784307B2 (pt)
BR (1) BRPI0107921B8 (pt)
CA (1) CA2399976C (pt)
CO (1) CO5271720A1 (pt)
CZ (1) CZ303400B6 (pt)
DE (1) DE60104978T3 (pt)
DK (1) DK1252170T4 (pt)
ES (1) ES2225481T5 (pt)
HK (1) HK1051046B (pt)
HU (1) HU230494B1 (pt)
IL (2) IL150511A0 (pt)
MA (1) MA25654A1 (pt)
MX (1) MXPA02007417A (pt)
MY (1) MY119968A (pt)
NO (1) NO329923B1 (pt)
NZ (1) NZ519966A (pt)
PE (1) PE20011061A1 (pt)
PL (1) PL207589B1 (pt)
PT (1) PT1252170E (pt)
RU (1) RU2236415C2 (pt)
SA (1) SA01220066B1 (pt)
SK (1) SK287884B6 (pt)
TR (1) TR200402435T4 (pt)
TW (1) TWI310769B (pt)
WO (1) WO2001056983A2 (pt)
ZA (1) ZA200205090B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410520B2 (en) * 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
AU2003209167A1 (en) * 2002-04-11 2003-10-27 Teva Pharmaceutical Industries Ltd Novel polymorphs and pseudopolymorphs of risedronate sodium
EP1923052A1 (en) 2002-04-11 2008-05-21 Teva Pharmaceutical Industries Ltd Novel polymorphs and pseudopolymorphs of risedronate sodium
CZ293349B6 (cs) 2002-10-25 2004-04-14 Léčiva, A.S. Nová krystalická forma sodné soli kyseliny 3-pyridyl-1-hydroxyethyliden-1,1-bisfosfonové
PT1583768E (pt) * 2003-01-17 2008-09-11 Teva Pharma Processo de redução do teor de ferro em risedronato de sódio
HUP0300227A2 (hu) * 2003-01-28 2004-09-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
BRPI0413067A (pt) * 2003-07-30 2006-10-17 Procter & Gamble processo para controlar a estrututra cristalina do risedronato
CZ298639B6 (cs) * 2004-02-05 2007-12-05 Zentiva, A. S. Krystalická forma risedronátu monosodného
PL1723157T5 (pl) * 2004-02-26 2018-01-31 Zentiva Ks Amorficzne postaci rizedronianu monosodowego
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
SI1753395T1 (sl) 2004-05-24 2011-01-31 Warner Chilcott Co Llc Enterične trdne formulacije oralnih odmerkov bifosfonata, ki vsebuje kelirno sredstvo
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
CA2590046A1 (en) * 2004-11-09 2006-05-18 Jubilant Organosys Limited Process for preparing a pure polymorphic form of 3-pyridyl-1-hydroxyethylidine-1,1-bisphosphonic acid sodium salt
PL199215B1 (pl) * 2004-12-28 2008-08-29 Politechnika Gdanska Sposób wytwarzania kwasu [1-hydroksy-2-(3-pirydylo)etylidenobisfosfonowego] oraz jego soli monosodowej dwu i pół wodnej
US20080194525A1 (en) * 2005-05-06 2008-08-14 Jordi Puig Serrano Process of Making Geminal Bisphosphonic Acids and Pharmaceutically Acceptable Salts and/or Hydrates Thereof
WO2006134603A1 (en) 2005-06-13 2006-12-21 Jubilant Organosys Limited Process for producing bisphosphonic acids and forms thereof
AR054673A1 (es) * 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
GB0519891D0 (en) * 2005-09-30 2005-11-09 Pliva Hrvatska D O O Pharmaceutically acceptable salts and hydrates
WO2007042048A2 (en) * 2005-10-11 2007-04-19 Sandoz A/S Method for preparing crystalline sodium risedronate
EP1775302A1 (en) * 2005-10-11 2007-04-18 Sandoz A/S Method for preparing crystalline sodium risedronate
EP1981896B1 (en) * 2006-01-20 2013-03-13 Aurobindo Pharma Limited An improved process for the preparation of risedronate sodium hemi-pentahydrate
AU2007226964B2 (en) * 2006-03-17 2012-03-22 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
JP5354858B2 (ja) * 2006-05-09 2013-11-27 株式会社Ａｄｅｋａ スルホンアミド化合物の金属塩を含有するポリエステル樹脂組成物
WO2007132478A2 (en) 2006-05-11 2007-11-22 Ind-Swift Laboratories Limited Process for the preparation of pure risedronic acid or salts
CA2656053A1 (en) * 2006-07-03 2008-01-10 Generics [Uk] Limited Novel process for the preparation of bisphosphonic acids
WO2008065542A2 (en) * 2006-09-22 2008-06-05 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for the preparation of risedronate sodium
WO2008044245A2 (en) * 2006-10-10 2008-04-17 Matrix Laboratories Ltd A process for the preparation of risedronate sodium hemipentahydrate
KR100828705B1 (ko) 2006-12-04 2008-05-09 씨제이제일제당 (주) 리세드론산 나트륨 수화물의 제조방법
KR100775440B1 (ko) * 2006-12-20 2007-11-12 동우신테크 주식회사 리세드로네이트 나트륨 헤미펜타히드레이트의 제조방법
KR100798855B1 (ko) * 2007-02-14 2008-01-28 주식회사 엔지켐 리세드론산 나트륨 헤미펜타하이드레이트의 제조방법
KR100812528B1 (ko) * 2007-04-12 2008-03-12 보령제약 주식회사 리세드로네이트 나트륨염의 헤미펜타히드레이트의 선택적결정화방법
WO2008152518A2 (en) * 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Process for the preparation of risedronic acid or risedronate sodium
WO2009050731A2 (en) * 2007-06-20 2009-04-23 Alkem Laboratories Ltd Novel process for preparing risedronic acid
DE102007030370A1 (de) 2007-06-29 2009-01-02 Ratiopharm Gmbh Essigsäure-Solvate von Risedronat, Polymorph hiervon, deren Herstellung und Verwendung sowie pharmazeutische Zusammensetzung, enthaltend diese
KR100925835B1 (ko) * 2007-12-07 2009-11-06 동우신테크 주식회사 리세드로네이트 나트륨 무수물 및 수화물의 제조방법
KR101010062B1 (ko) 2008-04-11 2011-01-21 주식회사 대희화학 증발 결정화를 이용한 결정상 리세드로네이트 모노소듐모노하이드레이트의 제조방법
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
EP3319970B1 (en) * 2015-07-08 2019-08-28 Daiichi Sankyo Company, Limited Pyrido-oxazinone derivatives as tnap inhibitors
EP3636683B1 (en) 2017-06-06 2023-09-06 Mitsubishi Chemical Corporation Polyorganosiloxane-containing graft copolymer, thermoplastic resin composition, and molded article

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
US4447256A (en) 1977-07-20 1984-05-08 Nissan Chemical Industries, Ltd. N-(Unsubstituted or substituted pyridyl)aminomethylene-diphosphonic acids, herbicidal compositions containing same, their use for herbicides, and process for preparing same
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4330537A (en) 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
JPS5598193A (en) 1979-01-22 1980-07-25 Nissan Chem Ind Ltd Methylenediphosphonic acid derivative and herbicide comprising it as active constituent
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
DE3151038A1 (de) 1981-12-23 1983-07-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von 3-amino-1-hydroxypropan-1,1-diphosphonsaeure
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
PH27078A (en) * 1984-12-21 1993-02-01 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonates
IT1187750B (it) 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di compresse,anche a rilascio prolungato,di iscsorbide-5-mononitrato stabilizzato e formulazioni cosi' ottenute
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
DE3773716D1 (de) 1986-03-24 1991-11-21 Nippon Kayaku Kk Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung.
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
DE3700772A1 (de) 1987-01-13 1988-07-21 Inst Khim Kinetiki I Gorenija Verfahren zur herstellung von i-funktionellsubstituierten alkyliden-i,i-diphosphonsaeuren und deren gemischen
US5091525A (en) 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US5035898A (en) 1987-11-27 1991-07-30 Schering Corporation Potassium/magnesium supplement
US5110807A (en) 1988-12-01 1992-05-05 Ciba-Geigy Corporation Araliphatylaminoalkanediphosphonic acids
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3917153A1 (de) 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
MX21453A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
MX21452A (es) 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
TW208013B (pt) 1990-03-01 1993-06-21 Daiichi Co Ltd
EP0544812B1 (en) 1990-08-21 1995-04-05 The Upjohn Company Bisphosphonic acid derivatives as anti-arthritic agents
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
IT1246992B (it) 1991-01-08 1994-12-12 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici e loro sali
DK58291D0 (da) 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
HU227530B1 (en) * 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
SE501389C2 (sv) 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US5317015A (en) 1992-05-01 1994-05-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Azacyclic bisphosphonates as anticholesterolemic agents
ATE173267T1 (de) 1992-06-23 1998-11-15 Yamanouchi Pharma Co Ltd Neues kristall von heterozyclischen bis(phosphonsäure) monohydrat-derivat
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
CA2161239A1 (en) 1993-04-28 1994-11-10 Douglas J.M. Allen Spirostanyl glycosidal crystalline monohydrate
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
TW257765B (pt) * 1993-08-25 1995-09-21 Merck & Co Inc
US5580977A (en) 1995-03-01 1996-12-03 Eli Lilly And Company Process for preparing loracarbef monohydrate
TW393488B (en) 1995-04-20 2000-06-11 Merck & Co Inc Process for making 1-hydrox-ybisphosphonates
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
ES2197329T3 (es) 1996-02-14 2004-01-01 Itzhak Binderman Bisfosfonatos topicos para la prevencion de la reabsorcion osea.
JP2000511178A (ja) 1996-05-17 2000-08-29 メルク エンド カンパニー インコーポレーテッド 発泡性ビスホスホネート製剤
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
KR100192215B1 (ko) 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
EP0989848B1 (en) * 1997-06-11 2004-09-29 The Procter & Gamble Company Film-coated tablet for improved upper gastrointestinal tract safety
ES2231919T3 (es) * 1997-07-15 2005-05-16 Gador S.A. Forma cristalina de sal monosodica monohidrato del acido n,n-dimetil-3-amino-1-hidroxipropano-1,1-difosfonico.
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
EP1089750A4 (en) * 1998-06-24 2001-10-04 Merck & Co Inc COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION.
WO2001045636A1 (en) * 1999-12-20 2001-06-28 Merck & Co., Inc. Pharmaceutical kit
US6410520B2 (en) * 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate

Also Published As

Publication number Publication date
WO2001056983A3 (en) 2002-03-07
CN1183148C (zh) 2005-01-05
PT1252170E (pt) 2004-12-31
IL150511A (en) 2006-12-10
MA25654A1 (fr) 2002-12-31
AU3473601A (en) 2001-08-14
RU2236415C2 (ru) 2004-09-20
TR200402435T4 (tr) 2004-12-21
CO5271720A1 (es) 2003-04-30
TWI310769B (en) 2009-06-11
DE60104978T2 (de) 2005-08-18
DK1252170T4 (da) 2014-01-20
EP1252170B1 (en) 2004-08-18
EP1252170B2 (en) 2013-11-06
EP1252170A2 (en) 2002-10-30
CA2399976C (en) 2007-03-27
DE60104978D1 (de) 2004-09-23
MXPA02007417A (es) 2002-12-09
HK1051046A1 (en) 2003-07-18
ATE273984T1 (de) 2004-09-15
NZ519966A (en) 2004-03-26
CZ303400B6 (cs) 2012-08-29
SA01220066B1 (ar) 2006-11-25
AR030187A1 (es) 2003-08-13
US6410520B2 (en) 2002-06-25
PL207589B1 (pl) 2011-01-31
JP2014208716A (ja) 2014-11-06
PL357097A1 (en) 2004-07-12
IL150511A0 (en) 2003-02-12
ES2225481T5 (es) 2014-02-19
JP2010159264A (ja) 2010-07-22
DE60104978T3 (de) 2014-04-03
DK1252170T3 (da) 2004-12-13
SK11002002A3 (sk) 2003-02-04
PE20011061A1 (es) 2001-11-20
ZA200205090B (en) 2003-04-30
KR100549038B1 (ko) 2006-02-02
HK1051046B (zh) 2005-04-29
NO20023645L (no) 2002-10-01
US20020002282A1 (en) 2002-01-03
SK287884B6 (sk) 2012-02-03
CA2399976A1 (en) 2001-08-09
JP5900553B2 (ja) 2016-04-06
JP2003521532A (ja) 2003-07-15
CN1396926A (zh) 2003-02-12
HUP0204203A3 (en) 2005-02-28
JP5405343B2 (ja) 2014-02-05
NO329923B1 (no) 2011-01-24
BRPI0107921B1 (pt) 2020-11-10
BRPI0107921B8 (pt) 2021-05-25
NO20023645D0 (no) 2002-07-31
ES2225481T3 (es) 2005-03-16
RU2002123369A (ru) 2004-01-10
HUP0204203A2 (en) 2003-05-28
JP2012255013A (ja) 2012-12-27
JP2016028083A (ja) 2016-02-25
KR20020071976A (ko) 2002-09-13
HU230494B1 (hu) 2016-09-28
JP5859930B2 (ja) 2016-02-16
AU784307B2 (en) 2006-03-09
WO2001056983A2 (en) 2001-08-09
MY119968A (en) 2005-08-30

Similar Documents

Publication Publication Date Title
BR0107921A (pt) Cristalização seletiva de sódio de ácido 3-piridil-1-hidroxietilideno-1,1-bisfosfÈnico como o monohidrato ou hemipentahidrato
MY119970A (en) Method of fertilizing an avian egg in the shell
YU70901A (sh) Derivati 1,4-benzotiazepin-1,1 dioksida zamenjeni radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
LV12735A (en) Manufacture and pharmaceutical compositions thereof
DK0636632T3 (da) Ikke-reducerende oligosaccharider og deres fremstilling og anvendelse
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
FI913137A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4"-deoksi-4"-epi-metyyliaminoavermekitiinisuolojen valmistamiseksi
WO2007128480A3 (en) Thioglycosides as pharmaceutically active agents
MXPA05014082A (es) Acidos biariloximetilarenocarboxilicos.
PL1751093T3 (pl) Podstawione pochodne kwasu cykloheksylooctowego
HUP0401141A2 (hu) A fluvasztatin-nátrium kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EE04552B1 (et) Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonid
WO2004017998A3 (en) Topical emulsion- gel composition comprising diclofenac sodium
PL366366A1 (en) Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same
AU2003273728A1 (en) A new crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid
ES2267421T1 (es) Procedimiento para la preparacion de acido (6rs)-n(5)-formil-5,6,7,8-tetrahidrofolico cristalino.
WO2003004460A3 (en) Succinic acid derivatives
MX2007007911A (es) Composicion farmaceutica granular estable de solifenacina o su sal.
MXPA03003466A (es) Derivados de piranosido.
MXPA04002400A (es) Sales de acidos salicilicos, metodos para su preparacion y su uso como medicamentos.
WO2002002758A3 (en) Crystallization and structure of staphylococcus aureus peptide deformylase
TH32609B (th) สูตรผสมทางเภสัชกรรมที่มีวอรีคอนาโซล์รวมอยู่ด้วย

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07F 9/58

Ipc: C07F 9/58 (2011.01), A61K 31/663 (2011.01), C07F 9

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

B25E Requested change of name of applicant rejected

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/02/2021

B25E Requested change of name of applicant rejected

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870220023196 DE 17/03/2022, EM VIRTUDE DA EXTINCAO (21.1) ART. 78 INCISO I DA LPI PUBLICADA NA RPI 2630 DE 01/06/2021.

B25B Requested transfer of rights rejected

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870220023209 DE 17/03/2022, EM VIRTUDE DA EXTINCAO (21.1) ART. 78 INCISO I DA LPI, PUBLICADA NA RPI2630 DE 01/06/2021.